Assess expiratory respiratory muscle strength
- Trial ID
- NCT07308795
- Official Title
- The Ultrasonographic Evaluation of Abdominal Accessory Respiratory Muscle Thickness in Patients With Parkinson's Disease: Correlation With Disease Severity and Expiratory Respiratory Muscle Strength
- Goal
- Assess expiratory respiratory muscle strength
- Status
- RECRUITING
- Sponsor
- Istanbul Physical Medicine Rehabilitation Training and Research Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 36 participants
- Conditions
- Parkinson Disease (PD), Maximum Inspiratory Pressure, Maximum Expiratory Pressure, Abdominal Accessory Respiratory Muscle Thickness
Plain-Language Summary
The goal is to find out whether thinner abdominal accessory breathing muscles, seen on ultrasound, are linked to worse Parkinson's severity and to weaker inhaling and exhaling pressures. The team uses noninvasive ultrasound to measure those muscle thicknesses and standard mouth-pressure tests called maximum inspiratory pressure and maximum expiratory pressure to see if muscle loss matches lower breathing strength, which could help flag respiratory problems earlier and guide breathing-focused care. Adults 18 to 75 with Parkinson's at Hoehn and Yahr stages 1,3, MMSE over 23, and BMI under 30 can join, while active smokers, people with active chest disease or unstable vitals, those whose Parkinson's is not controlled with medication, and Parkinson-plus syndromes are excluded.
Locations
- İstanbul Fizik Tedavi Ve Rehabilitasyon Eğitim Ve Araştirma Hastanesi, Istanbul, BAHÇELİEVLER, Turkey (Türkiye)
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to find out whether thinner abdominal accessory breathing muscles, seen on ultrasound, are linked to worse Parkinson's severity and to weaker inhaling and exhaling pressures. The team uses noninvasive ultrasound to measure those muscle thicknesses and standard mouth-pressure tests called maximum inspiratory pressure and maximum expiratory pressure to see if muscle loss matches lower breathing strength, which could help flag respiratory problems earlier and guide breathing-focused care. Adults 18 to 75 with Parkinson's at Hoehn and Yahr stages 1,3, MMSE over 23, and BMI under 30 can join, while active smokers, people with active chest disease or unstable vitals, those whose Parkinson's is not controlled with medication, and Parkinson-plus syndromes are excluded.
- Who can participate?
- Participants must be between 18 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 months.